Welcome to the Hope Bio Blog

Written by Jan Shultis Billions of stem cells manufactured through proprietary technology by Houston-area biotechnology company Hope Biosciences are soon to be pressed into the fight against Alzheimer’s Disease (AD). The U.S. Food and Drug Administration (FDA) has authorized an open label Phase Ib/IIa clinical trial to evaluate whether Hope Biosciences autologous, adipose-derived mesenchymal stem cells (HB-adMSCs) reduce inflammation in the brain, improve brain activity, an

A Mid-year Introduction to Hope Bio's Community | Written by Jan Shultis About six months ago, did you resolve that this would be a new year, and a new "you"? As summer proceeds and coaches in seemingly every field start to ask how we're doing with those resolutions set back in January, maybe it's time for a pivot - what about “new year, same you,” but “now healthier and optimally protected against threats like degenerative disease or catastrophic illness?” If that resonates,

Written by Jan Shultis Sugar Land, Texas, 1 NOV 2024: Hope Biosciences, a clinical-stage biotechnology company that manufactures mesenchymal stem cell therapeutics through proprietary technology unprecedented in its ability to create repeatable treatments, today shares positive top-line results of a Phase II clinical trial to evaluate Hope Biosciences’ adipose‑derived autologous mesenchymal stem cell therapy (HB-adMSCs) for patients with mild to moderate relapsing remitting m